Krystal Biotech, Inc.
KRYS
Rang in Aktien
#2154
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on... Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
Aktienkurs
$320.50
Zuletzt synchronisiert: 2026-10-19
Marktkapitalisierung
$9.49B
Veränderung (1 Tag)
1.24%
Veränderung (1 Jahr)
63.55%
Land
US
Handel Krystal Biotech, Inc. (KRYS)
Kategorie
Healthcare
P/S-Verhältnis für Krystal Biotech, Inc. (KRYS)
P/S-Verhältnis zum October 2026 TTM: 22.22
Laut den neuesten Finanzberichten und dem Aktienkurs von Krystal Biotech, Inc. beträgt das aktuelle Kurs-Umsatz-Verhältnis (TTM) 22.22. Am Ende des Jahres 2023 lag das P/S-Verhältnis bei 66.45.
P/S-Verlauf für Krystal Biotech, Inc. von 2016 bis 2026
P/S-Verhältnis zum Jahresende
| Jahr | P/S-Verhältnis | ändert |
|---|---|---|
| 2026 (TTM) | 22.22 | 44.11% |
| 2024 | 15.42 | -76.80% |
| 2023 | 66.45 | 0.00% |
| 2022 | 0.00 | 0.00% |
| 2021 | 0.00 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | -100.00% |
| 2018 | 226.68 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
P/S-Verhältnis für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | P/S-Verhältnis | P/S-Verhältnis-Differenz | Land |
|---|---|---|---|
| 10.02 | -54.90% |
US
|
|
| 40.55 | 82.49% |
US
|
|
| 3.96 | -82.17% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | -54.34% |
NL
|
